Business
PAVmed Appoints Joseph Virgilio to Lead Relaunched Medical Device Portfolio
Medtech industry veteran to oversee development and commercialization of PAVmed's current and future medical device portfolio.Octeris, Inc. subsidiary formed
About this update from Pavmed Inc.
[{"type":"text","content":"Medtech industry veteran to oversee development and commercialization of PAVmed's current and future medical device portfolio.Octeris, Inc. subsidiary formed to advance endoscopic esophageal imaging technology recently licensed from Duke University.NEW YORK, April 2, 2026 /PRNewswire/ -- PAVmed Inc. (Nasdaq: PAVM) (\"PAVmed\" or the \"Company\"), a diversified commercial-stage medical technology company, operating in the medical device, diagnostics, and digital health sectors, today announced that it has appointed medical technology industry veteran Joseph Virgilio as Senior Vice President and Chief Business Officer, Medical Devices to oversee the development and commercialization of PAVmed's current and future medical device portfolio.\n \n \n \n \n \n \n \n\"Fixing PAVmed's capital structure and strengthening our balance sheet has allowed us to proceed with the long-anticipated relaunch our medical device portfolio under dedicated, experienced leadership,\" said PAVmed Chairman and Chief Executive Officer, Lishan Aklog, M.D. \"We look forward to leveraging Mr. Virgilio's deep sector experience and leadership as we advance our existing medical device programs, while seeking to expand our pipeline with significant commercial opportunities which enhance long-term shareholder value. This relaunch is consistent with our mission to build a high-growth diversified commercial life sciences company with multiple independently financed subsidiaries operating under a shared services model.\"Medical Device LeadershipMr. Virgilio brings over 25 years of leadership experience across the medical device industry, with a track record of building and scaling medical technology businesses, advancing products from development through regulatory approval and commercialization, raising public and private capital, and establishing strategic partnerships.Mr. Virgilio most recently served as President and Chief Executive Officer of Morphic Medical, a clinical-stage company in the gastrointestinal and metabolic intervention space. He led the company's commercial and operational strategy, advanced key regulatory initiatives including EU approvals and a U.S. FDA pre-market authorization (PMA) study, during which time the company secured over $40 million in capital to support growth and execution.Mr. Virgilio has extensive prior experience building and sc...